Canakinumab for treatment of adult onset Still's disease to achieve reduction of arthritic manifestation
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Canakinumab (Primary)
- Indications Adult-onset Still's disease
- Focus Therapeutic Use
- Acronyms CONSIDER
- 25 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
- 25 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
- 13 Apr 2013 Status changed from suspended to recruiting as reported by European Clinical Trials Database record.